RxSight, Inc. (RXST) stock

RXSTNasdaqOphthalmic GoodsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3074% below fair value

$5.32−0.06 (-1.12%)

Close on Nov 13, 2026Market cap $221.28MP/E –Yield –

RxSight r&d expenses

Research and development expenses are spending on new products and technology.

RxSight's R&D Expenses for the twelve months ending Jun 30, 2026 was $36.67M, down 5.1% year over year. For fiscal 2025 it was $38.55M, up 12.2% from the year before. The highest annual figure on record is $38.55M in fiscal 2025.

Annual r&d expenses

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$38.55M	+12.2%
FY2024	Dec 31, 2024	$34.37M	+18.3%
FY2023	Dec 31, 2023	$29.05M	+11.8%
FY2022	Dec 31, 2022	$25.98M	+6.0%
FY2021	Dec 31, 2021	$24.50M	+11.7%
FY2020	Dec 31, 2020	$21.93M	–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q2 FY2026	Jun 30, 2026	$9.24M	-9.6%
Q1 FY2026	Mar 31, 2026	$9.47M	-8.6%
Q4 FY2025	Dec 31, 2025	$8.91M	-3.3%
Q3 FY2025	Sep 30, 2025	$9.06M	+2.5%
Q2 FY2025	Jun 30, 2025	$10.22M	+23.2%
Q1 FY2025	Mar 31, 2025	$10.37M	+29.1%
Q4 FY2024	Dec 31, 2024	$9.21M	+25.4%
Q3 FY2024	Sep 30, 2024	$8.84M	+24.5%
Q2 FY2024	Jun 30, 2024	$8.29M	+12.0%
Q1 FY2024	Mar 31, 2024	$8.03M	+11.4%
Q4 FY2023	Dec 31, 2023	$7.34M	+9.9%
Q3 FY2023	Sep 30, 2023	$7.10M	+11.2%
Q2 FY2023	Jun 30, 2023	$7.40M	+19.5%
Q1 FY2023	Mar 31, 2023	$7.21M	+7.3%
Q4 FY2022	Dec 31, 2022	$6.68M	+12.9%
Q3 FY2022	Sep 30, 2022	$6.39M	+18.8%
Q2 FY2022	Jun 30, 2022	$6.19M	-5.7%
Q1 FY2022	Mar 31, 2022	$6.72M	+1.1%
Q4 FY2021	Dec 31, 2021	$5.92M	+12.2%
Q3 FY2021	Sep 30, 2021	$5.38M	-7.3%
Q2 FY2021	Jun 30, 2021	$6.56M	+29.1%
Q1 FY2021	Mar 31, 2021	$6.64M	–
Q4 FY2020	Dec 31, 2020	$5.27M	–
Q3 FY2020	Sep 30, 2020	$5.80M	–
Q2 FY2020	Jun 30, 2020	$5.08M	–